Literature DB >> 14612519

Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia.

Ralf Bieker1, Teresa Padró, Julia Kramer, Martin Steins, Torsten Kessler, Stephan Retzlaff, Federico Herrera, Joachim Kienast, Wolfgang E Berdel, Rolf M Mesters.   

Abstract

Basic fibroblast growth factor (bFGF) is known to play a critical role in tumorigenesis of solid tumors. The importance of bFGF in hematological malignancies such as acute myeloid leukemia (AML) remains to be elucidated. Therefore, we determined bFGF protein expression by immunohistochemical analyses in bone marrow biopsies of patients with newly diagnosed, untreated AML. The expression of bFGF was significantly increased in AML patients [n = 81; median, 3.0 (interquartile range, 1.8-3.9) arbitrary units (AU)] as compared with controls [n = 18; 1.9 (1.5-2.3) AU]. The degree of bFGF expression did not correlate with microvessel density. bFGF/FGF receptor mRNA and bFGF protein were detected in different AML cell lines. To study autocrine growth stimulation of AML blasts, the AML cell lines HL-60, M-07e, and KG-1 were incubated with bFGF. A significant dose-dependent increase in proliferation and colony formation was observed. These effects were abrogated by the addition of a polyclonal anti-bFGF antibody. In conclusion, increased expression of bFGF in the bone marrow of AML patients seems to play an important role in the pathophysiology of AML by promoting autocrine growth stimulation of leukemic blasts.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14612519

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Extracellular matrix-modulated Heartless signaling in Drosophila blood progenitors regulates their differentiation via a Ras/ETS/FOG pathway and target of rapamycin function.

Authors:  Michelle Dragojlovic-Munther; Julian A Martinez-Agosto
Journal:  Dev Biol       Date:  2013-04-18       Impact factor: 3.582

2.  A peptide derivative serves as a fibroblast growth factor 2 antagonist in human gastric cancer.

Authors:  Lei Fan; Wulan Li; Shilong Ying; Lingyi Shi; Zhe Wang; Gaozhi Chen; Hui Ye; Xiaoping Wu; Jianzhang Wu; Guang Liang; Xiaokun Li
Journal:  Tumour Biol       Date:  2015-04-19

3.  The lack of Raf-1 kinase feedback regulation enhances antiapoptosis in cancer cells.

Authors:  S Q Ma; B R Cao; H Zhang; L P Luo; Y Ren; T Hu; C M Chen
Journal:  Oncogene       Date:  2016-11-14       Impact factor: 9.867

4.  Soluble angiopoietin-2/sTie2 receptor ratio is an independent prognostic marker in adult acute myeloid leukemia.

Authors:  Salah Aref; Nadia El Menshawy; Emaad Azmy; Mohamed El-Refaie
Journal:  Indian J Hematol Blood Transfus       Date:  2009-04-06       Impact factor: 0.900

Review 5.  Contribution of bone microenvironment to leukemogenesis and leukemia progression.

Authors:  F Ayala; R Dewar; M Kieran; R Kalluri
Journal:  Leukemia       Date:  2009-09-03       Impact factor: 11.528

6.  ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.

Authors:  Deepa B Shankar; Junling Li; Paul Tapang; J Owen McCall; Lori J Pease; Yujia Dai; Ru-Qi Wei; Daniel H Albert; Jennifer J Bouska; Donald J Osterling; Jun Guo; Patrick A Marcotte; Eric F Johnson; Niru Soni; Kresna Hartandi; Michael R Michaelides; Steven K Davidsen; Saul J Priceman; Jenny C Chang; Katrin Rhodes; Neil Shah; Theodore B Moore; Kathleen M Sakamoto; Keith B Glaser
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

Review 7.  (Lymph)angiogenic influences on hematopoietic cells in acute myeloid leukemia.

Authors:  Ji Yoon Lee; Hee-Je Kim
Journal:  Exp Mol Med       Date:  2014-11-21       Impact factor: 8.718

8.  A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.

Authors:  Christoph Schliemann; Joachim Gerss; Stefanie Wiebe; Jan-Henrik Mikesch; Nicola Knoblauch; Tim Sauer; Linus Angenendt; Tobias Kewitz; Marc Urban; Trude Butterfass-Bahloul; Sabine Edemir; Kerstin Vehring; Carsten Müller-Tidow; Wolfgang E Berdel; Utz Krug
Journal:  PLoS One       Date:  2016-10-07       Impact factor: 3.240

9.  Expression and clinical significance of serum MMP-7 and PTEN levels in patients with acute myeloid leukemia.

Authors:  Jiang Wu; Yu Song
Journal:  Oncol Lett       Date:  2018-01-15       Impact factor: 2.967

Review 10.  Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies.

Authors:  Mohamed R Akl; Poonam Nagpal; Nehad M Ayoub; Betty Tai; Sathyen A Prabhu; Catherine M Capac; Matthew Gliksman; Andre Goy; K Stephen Suh
Journal:  Oncotarget       Date:  2016-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.